156 related articles for article (PubMed ID: 37453413)
21. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
22. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
23. Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives.
Nazarizadeh A; Staudacher AH; Wittwer NL; Turnbull T; Brown MP; Kempson I
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563097
[TBL] [Abstract][Full Text] [Related]
24. Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines.
Da Silva CG; Camps MGM; Li TMWY; Chan AB; Ossendorp F; Cruz LJ
Biomaterials; 2019 Nov; 220():119417. PubMed ID: 31419588
[TBL] [Abstract][Full Text] [Related]
25. Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4
Melssen MM; Fisher CT; Slingluff CL; Melief CJM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36939214
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for pancreatic cancer: current concepts.
Kaufman HL; Di Vito J; Hörig H
Hematol Oncol Clin North Am; 2002 Feb; 16(1):159-97, viii. PubMed ID: 12063825
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic cancer: a review of recent advances.
Eckel F; Schneider G; Schmid RM
Expert Opin Investig Drugs; 2006 Nov; 15(11):1395-410. PubMed ID: 17040199
[TBL] [Abstract][Full Text] [Related]
28. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
Obeid J; Hu Y; Slingluff CL
Semin Oncol; 2015 Aug; 42(4):549-61. PubMed ID: 26320060
[TBL] [Abstract][Full Text] [Related]
29. CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach.
Zhang X; Hu Q; He X; Cui X; Liang Z; Wang L; Deng X; Zhang Z; Sheng W; Han XD
J Nanobiotechnology; 2023 May; 21(1):159. PubMed ID: 37208748
[TBL] [Abstract][Full Text] [Related]
30. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
31. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
Banday AH; Jeelani S; Hruby VJ
Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
[TBL] [Abstract][Full Text] [Related]
32. mRNA-encoded, constitutively active STING
Tse SW; McKinney K; Walker W; Nguyen M; Iacovelli J; Small C; Hopson K; Zaks T; Huang E
Mol Ther; 2021 Jul; 29(7):2227-2238. PubMed ID: 33677092
[TBL] [Abstract][Full Text] [Related]
33. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
Immunotherapy; 2016 Feb; 8(2):117-25. PubMed ID: 26787078
[TBL] [Abstract][Full Text] [Related]
34. Nanovaccine: an emerging strategy.
Das A; Ali N
Expert Rev Vaccines; 2021 Oct; 20(10):1273-1290. PubMed ID: 34550859
[TBL] [Abstract][Full Text] [Related]
35. Overcoming cancer immune tolerance and escape.
Clifton GT; Peoples GE
Clin Cancer Res; 2009 Feb; 15(3):749-51. PubMed ID: 19188142
[TBL] [Abstract][Full Text] [Related]
36. Mutated Ras peptides as vaccines in immunotherapy of cancer.
Gjertsen MK; Gaudernack G
Vox Sang; 1998; 74 Suppl 2():489-95. PubMed ID: 9704487
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4.
Kang TH; Kim YS; Kim S; Yang B; Lee JJ; Lee HJ; Lee J; Jung ID; Han HD; Lee SH; Koh SS; Wu TC; Park YM
Oncotarget; 2015 Sep; 6(29):27751-62. PubMed ID: 26336989
[TBL] [Abstract][Full Text] [Related]
38. Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer.
Zhang X; Xu Z; Dai X; Zhang X; Wang X
Front Immunol; 2023; 14():1104860. PubMed ID: 36761724
[TBL] [Abstract][Full Text] [Related]
39. Vaccine-like nanomedicine for cancer immunotherapy.
Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
[TBL] [Abstract][Full Text] [Related]
40. Frontiers in adjuvant therapy in stage II-III melanoma.
Eggermont AM
Tumori; 2001; 87(4):S60-3. PubMed ID: 11693827
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
